On the threshold of a new era in our understanding of Parkinson’s disease
We believe that by sharing our knowledge and insights we can expand our impact and get us all closer to alleviating the burdens of those suffering from Parkinson’s and other neurological disorders.
Our lead scientists meet often to assess, analyze, and dig deeper into the latest research news and developments, drawing on their many decades of world-leading neuroscience and preclinical expertise, to promote discussion and engagement around the issues, challenges, and dynamics shaping both the scientific and commercial development of new therapeutics. This is how we do science everyday.
NEWS & insights
-
New frontiers in inflammasome therapeutics
-
Atuka releases its latest white paper, on the future of gene therapy
-
Announcing a $1.5m collaboration with Kannalife Sciences and Michael J. Fox Foundation
-
What the market overlooked in Seelos’s recent trehalose study
-
Atuka welcomes new board member Ian Lennox
WHITE PAPER
The future of gene therapy from a pre-clinical perspective
The potential of gene therapies is finally being realized and these therapies can deliver life-changing treatments for a broad range of disorders.
Atuka’s Chief Innovation Officer Dr Patrick A. Howson explores the past, present, and future of gene therapy.
TALK TO OUR EXPERTS